組織金屬蛋白酶抑制因子2(TIMP2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Tissue Inhibitors Of Metalloproteinase 2 (TIMP2)
CSC-21K; TIMP Metallopeptidase Inhibitor 2
- 編號(hào)SEA128Hu
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍0.94-60ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.37ng/mL.
- 樣本類型serum, plasma and other biological fluids
- 下載英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 2646¥ 3780¥ 17010¥ 32130¥ 264600
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線圖
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)組織金屬蛋白酶抑制因子2(TIMP2)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的組織金屬蛋白酶抑制因子2(TIMP2)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 91-103 | 98 |
| EDTA plasma(n=5) | 93-101 | 97 |
| heparin plasma(n=5) | 99-105 | 102 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的組織金屬蛋白酶抑制因子2(TIMP2)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中組織金屬蛋白酶抑制因子2(TIMP2)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 85-93% | 85-93% | 79-98% | 97-105% |
| EDTA plasma(n=5) | 91-98% | 86-94% | 96-103% | 95-103% |
| heparin plasma(n=5) | 83-95% | 80-98% | 87-101% | 78-101% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將組織金屬蛋白酶抑制因子2(TIMP2)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的組織金屬蛋白酶抑制因子2(TIMP2)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的組織金屬蛋白酶抑制因子2(TIMP2)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的組織金屬蛋白酶抑制因子2(TIMP2)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| APA128Hu02 | 組織金屬蛋白酶抑制因子2(TIMP2)活性蛋白 | Cell?culture;?Activity?Assays. |
| APA128Hu01 | 組織金屬蛋白酶抑制因子2(TIMP2)活性蛋白 | Cell?culture;?Activity?Assays. |
| EPA128Hu61 | 組織金屬蛋白酶抑制因子2(TIMP2)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA128Hu61 | 組織金屬蛋白酶抑制因子2(TIMP2)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA128Hu02 | 組織金屬蛋白酶抑制因子2(TIMP2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA128Hu03 | 組織金屬蛋白酶抑制因子2(TIMP2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA128Hu03 | 組織金屬蛋白酶抑制因子2(TIMP2)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA128Hu01 | 組織金屬蛋白酶抑制因子2(TIMP2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA128Hu01 | 組織金屬蛋白酶抑制因子2(TIMP2)多克隆抗體 | WB; IHC |
| PAA128Hu06 | 組織金屬蛋白酶抑制因子2(TIMP2)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA128Hu71 | 組織金屬蛋白酶抑制因子2(TIMP2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAA128Hu22 | 組織金屬蛋白酶抑制因子2(TIMP2)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA128Hu | 組織金屬蛋白酶抑制因子2(TIMP2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA128Hu | 組織金屬蛋白酶抑制因子2(TIMP2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| The Journal of Nutrition | Oral Administration of 3,3′-Diindolylmethane Inhibits Lung Metastasis of 4T1 Murine Mammary Carcinoma Cells in BALB/c Mice[Nutrition&Metabolism: source] |
| Breast Cancer Research and Treatment | Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice[SpringerLink: f3w831267267p277] |
| Moleculer Vision | Bone morphogenetic protein-2: a potential regulator in scleral remodeling[PubMed: PMC2605409] |
| Experimental & Translational Stroke Medicine | Early outcome and blood-brain barrier integrity after co-administered thrombolysis and hyperbaric oxygenation in experimental stroke[PubMed: 21679435] |
| PLoS ONE | A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic Approaches[Plosone: Source] |
| Polski Przeglad Chirurgiczny | Concentration of gelatinases and their tissue inhibitors in pancreatic inflammatory and neoplastic tumors and their influence on the early postoperative course[Pubmed: 23585206] |
| Thromb Haemost. | Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic stroke[Pubmed:24671655] |
| Pediatric Anesthesia? | Impact of 6% hydroxyethyl starch 130/0.42 and 5% gelatin on renal function in a pediatric animal model[Pubmed:24916275] |
| PLOS ONE | The Complementary Effects of Atorvastatin and Exercise Treatment on the Composition and Stability of the Atherosclerotic Plaques in ApoE Knockout Mice[Pubmed:25264981] |
| Brain, Behavior, and Immunity | Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model [Pubmed:25266150] |
| Mediators of Inflammation | Metalloproteinases and Their Tissue Inhibitors in Comparison between Different Chronic Pneumopathies in the Horse[Journals: Mi] |
| Brain, Behavior, and Immunity | Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model[PubMed: 25266150] |
| physiological research | The skin remodeling in type 1 diabetes and insulin resistance animal models[PubMed: 26047379] |
| Physiol Res | The skin remodeling in type 1 diabetes and insulin resistance animal models.[PubMed: 26047379] |
| J Periodontal Implant Sci | Assessment of MMP-1, MMP-8 and TIMP-2 in experimental periodontitis treated with kaempferol[pmc:PMC4848383] |
| Int Wound J. | From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases.[Pubmed:26991748] |
| BMC Veterinary Research | Metalloproteinases?and their?inhibitors?are?influenced?by?inhalative?glucocorticoid?therapy?incombination?with?environmental?dust?reduction?in?equine?recurrent airway obstruction.[pubmed:27938355] |
| Journal of Applied Animal Research | Hypoxia enhances secretion of matrix metalloproteinases in bovine dermal fibroblasts:an in vitro approach to bovine digital dermatitis [10.108:09712119.2017.1335208] |
| Cellular Physiology and Biochemistry | The MiR-495/Annexin A3/P53 Axis Inhibits the Invasion and EMT of Colorectal Cancer Cells[pubmed:29224019] |
| International Wound Journal | From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases[pubmed:26991748] |
| Journal of Applied Animal Research? | Hypoxia enhances secretion of matrix metalloproteinases in bovine dermal fibroblasts: an approach to bovine digital dermatitis[10.1080:09712119.2017.1335208] |
| Mediators of Inflammation | Metalloproteinases and their Inhibitors under the Course of Immunostimulation by CPG-ODN and Specific Antigen Inhalation in Equine Asthma[] |
| Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists | Correlation of Baseline Plasma and Inguinal Connective Tissue Metalloproteinases and Their Inhibitors With Late High-Pressure Endoleak After Endovascular?…[Pubmed: 31464166] |
| Scientific Reports | Matrix metallopeptidase expression and modulation by transforming growth factor-β1 in equine endometrosis[Pubmed: 31980722] |
| MEDIATORS OF INFLAMMATION | MMP-9 Concentration in Peritoneal Fluid Is a Valuable Biomarker Associated with Endotoxemia in Equine Colic[33488296] |
| Calcium Binding Protein S100A16 Expedites Proliferation, Invasion and EMT Process in Gastric Cancer[34650982] |
